Fig. 7: Concurrent CDK9i augments anti-tumor effect of IR to prolong survival in vivo.

a. Schematic represents the treatment schedule of SU-DIPG13* xenografts with either AZD4573 (15/15 mg/kg biweekly administered intraperitoneally), radiotherapy (2 Gy x 3 fractions), or combination. b. Kaplan-Meier survival analysis of SU-DIPG13* flank cohorts receiving indicated treatments. Comparison reflects p value of Mantel-Cox log-rank test (control n = 4, AZD4573 n = 5, IR n = 3, AZD + IR n = 4). c. Bioluminescent imaging from median mouse of each treatment cohort in (B) at completion of therapy period. d. Schematic representation of schedule for SU-DIPG13* xenografts treated with either zotiraciclib (ZTR, 50 mg/kg 3x weekly for two weeks followed by 35 mg/kg 3x weekly for two weeks, administered by oral gavage), radiotherapy (2 Gy x 3 fractions), or combination. e. Bioluminescent flux from individual animals within indicated treatment groups (two-tailed Mann-Whitney test at completion of treatment, p value in insert). f. Kaplan-Meier survival analysis of orthotopic xenograft cohorts receiving indicated treatments. Comparison reflects p value of Mantel-Cox log-rank test (control n = 6, ZTR n = 6, IR n = 6, ZTR + IR n = 5). g. Representative axial T2-weighted turboRARE MRI sequences of IR- or ZTR + IR-treated mice. Arrowheads indicate margins of tumor; white text overlay denotes three-dimensional tumor volume. Comparison of tumor volume quantification shown on right (p value of two-tailed Student’s t-test, IR n = 8, ZTR + IR n = 9). Box plots display interquartile range, median, and whisker (minimum to maximum). Source data are provided as a Source Data file.